Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights

Acneiform rash is the most common side effect of epidermal growth factor receptor (EGFR) inhibitors (EGFRis), and it occurs in 50–100% of patients. This condition can affect the quality of life of these patients and can sometimes lead to a discontinuation of the antineoplastic therapy. Several recent prospective studies have addressed and evaluated different interventions to mitigate or reduce the severity of EGFRisassociated skin rash. With this aim, we have established a dermocosmetological outpatient clinic for cancer patients at the Department of Clinical Medicine and Surgery, University of Naples Federico II in collaboration with the Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami. An interdisciplinary network of physicians can improve the quality of life of the cancer patients, focusing on such important aspects as dermocosmetological skin care, but also on the evaluation of new therapeutic and diagnostic algorithms in order to make further progress in the field of prevention. In this review, we summarize the state of the art of the epidemiology, pathogenesis, and treatment of EGFRis acneiform rash, and we describe our outpatient clinical experience. © 2015 S. Karger AG, Basel Received: November 18, 2014 Accepted: December 31, 2014 Published online: February 13, 2015 Gabriella Fabbrocini Section of Dermatology, Department of Clinical Medicine and Surgery University of Naples Federico II, Via Sergio Pansini 5 IT–80132 Naples (Italy) E-Mail gafabbro @ unina.it © 2015 S. Karger AG, Basel 2296–9195/15/0011–0031$39.50/0